Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARDELYX, INC.ARDX · Entity 4972 | Director | June 16, 2026 | June 18, 2026 |
| Arcus Biosciences, Inc.RCUS · Entity 4104 | Director | July 13, 2020 | July 13, 2020 |
| ArriVent BioPharma, Inc.AVBP · Entity 4699 | Director | June 18, 2026 | June 23, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Medical Officer | December 10, 2024 | December 12, 2024 |
| Sagimet Biosciences Inc.SGMT · Entity 5273 | Director | June 05, 2024 | June 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARDELYX, INC.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 83,746 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 26,455 · Balance 83,746 F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.67 · Expires 2036-06-16 | Direct | 39,715 |
Reported balance
After 2026-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-16 · Grant · Acquired 39,715 · Balance 39,715 F2: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program.
F2: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program.
F3: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.
Arcus Biosciences, Inc.
Report date July 13, 2020 · Filed July 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2020-07-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
ArriVent BioPharma, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.74 · Expires 2036-06-17 | Direct | 13,562 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 13,562 · Balance 13,562 F1: The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date.
GILEAD SCIENCES, INC.
Report date December 10, 2024 · Filed December 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,850 |
Ending reported balance
After 2024-12-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-12-10 · Exercise / conversion · Acquired 3,820 · Balance 84,621 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Row 2 · 2024-12-10 · Tax withholding · Disposed 1,771 · Balance 82,850 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 36,753 |
Reported balance
After 2024-12-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-12-10 · Exercise / conversion · Disposed 3,820 · Balance 36,753 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F2: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Sagimet Biosciences Inc.
Report date June 05, 2024 · Filed June 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 · Expires 2034-06-04 | Direct | 51,459 |
Reported balance
After 2024-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-05 · Grant · Acquired 51,459 · Balance 51,459 F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 5, 2024, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 5, 2024, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 01:51 UTC | ArriVent BioPharma, Inc. AVBP · Entity 4699 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,562 | $0.00 Strike: $31.74 | $0.00 |
DisclosureSEC source: 0001104659-26-076570 · tm2618519-4_4seq1.xml · derivative · entry 1 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,562 Underlying: Common Stock · 13,562 shares Expires 2036-06-17 F1 · derivative.exercise_date: The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 21:14 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 39,715 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001792150-26-000002 · wk-form4_1781817269.xml · derivative · entry 2 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,715 Underlying: Common Stock · 39,715 shares Expires 2036-06-16 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 21:14 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 26,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001792150-26-000002 · wk-form4_1781817269.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,746 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 23:33 UTC | ArriVent BioPharma, Inc. AVBP · Entity 4699 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,502 | $0.00 Strike: $24.89 | $0.00 |
DisclosureSEC source: 0001104659-25-061270 · tm2518583-4_4seq1.xml · derivative · entry 1 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,502 Underlying: Common Stock · 15,502 shares Expires 2035-06-17 Read SEC document |
| June 18, 2025 Filed Jun 24, 2025 00:41 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 15,235 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-032728 · wk-form4_1750725671.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,291 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document |
| April 28, 2025 Filed Apr 29, 2025 20:51 UTC | ArriVent BioPharma, Inc. AVBP · Entity 4699 | GrantStock Option (right to buy) · Derivative | 28,346 | $0.00 Strike: $20.92 | $0.00 |
DisclosureSEC source: 0001104659-25-041344 · tm2513488-2_4seq1.xml · derivative · entry 1 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,346 Underlying: Common Stock · 28,346 shares Expires 2035-04-27 F1 · derivative.exercise_date: These options vest annually in equal installments over three years, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| April 28, 2025 Filed May 14, 2025 23:51 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 64,457 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001628280-25-025641 · wk-form4_1747266667.xml · derivative · entry 2 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,457 Underlying: Common Stock · 64,457 shares Expires 2035-04-28 F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 36 successive, equal monthly installments on each monthly anniversary of April 28, 2025, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| April 28, 2025 Filed May 14, 2025 23:51 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 42,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-025641 · wk-form4_1747266667.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,056 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 00:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-029171 · form4.xml · derivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,753 Underlying: Common Stock · 3,820 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 00:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,771 | $92.34 | $163,534.14 |
DisclosureSEC source: 0001127602-24-029171 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,850 Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 00:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-029171 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| November 27, 2024 Filed Nov 30, 2024 01:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 88,119 | $0.00 Strike: $65.38 | $0.00 |
DisclosureSEC source: 0001127602-24-028232 · form4.xml · derivative · entry 9 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196 Underlying: Common Stock · 88,119 shares Expires 2029-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 27, 2024 Filed Nov 30, 2024 01:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 57,294 | $0.00 Strike: $57.92 | $0.00 |
DisclosureSEC source: 0001127602-24-028232 · form4.xml · derivative · entry 8 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,376 Underlying: Common Stock · 57,294 shares Expires 2032-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 27, 2024 Filed Nov 30, 2024 01:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,399 | $92.00 | $956,708.00 |
DisclosureSEC source: 0001127602-24-028232 · form4.xml · nonDerivative · entry 7 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,801 Read SEC document |
| November 27, 2024 Filed Nov 30, 2024 01:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,199 | $91.80 | $293,679.08 |
DisclosureSEC source: 0001127602-24-028232 · form4.xml · nonDerivative · entry 6 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,200 F3 · price: Sale prices reported for the transactions reported here range from $91.451 to $92.035. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 27, 2024 Filed Nov 30, 2024 01:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,200 | $91.80 | $477,381.32 |
DisclosureSEC source: 0001127602-24-028232 · form4.xml · nonDerivative · entry 5 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,399 F2 · price: Sale prices reported for the transactions reported here range from $91.458 to $92.04. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 27, 2024 Filed Nov 30, 2024 01:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 88,119 | $92.00 | $8,106,948.00 |
DisclosureSEC source: 0001127602-24-028232 · form4.xml · nonDerivative · entry 4 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,599 Read SEC document |
| November 27, 2024 Filed Nov 30, 2024 01:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 57,294 | $91.79 | $5,259,297.00 |
DisclosureSEC source: 0001127602-24-028232 · form4.xml · nonDerivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,718 F1 · price: Sale prices reported for the transactions reported here range from $91.451 to $92.095. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 27, 2024 Filed Nov 30, 2024 01:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 88,119 | $65.38 | $5,761,220.22 |
DisclosureSEC source: 0001127602-24-028232 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 245,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2024 Filed Nov 30, 2024 01:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 57,294 | $57.92 | $3,318,468.48 |
DisclosureSEC source: 0001127602-24-028232 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2024 Filed Nov 7, 2024 21:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $57.92 | $0.00 |
DisclosureSEC source: 0001127602-24-026735 · form4.xml · derivative · entry 4 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,670 Underlying: Common Stock · 25,000 shares Expires 2032-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023. F2 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 06, 2024 Filed Nov 7, 2024 21:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $91.50 | $457,500.00 |
DisclosureSEC source: 0001127602-24-026735 · form4.xml · nonDerivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,599 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023. Read SEC document |
| November 06, 2024 Filed Nov 7, 2024 21:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 20,590 | $91.50 | $1,883,985.00 |
DisclosureSEC source: 0001127602-24-026735 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,599 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023. Read SEC document |
| November 06, 2024 Filed Nov 7, 2024 21:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 25,000 | $57.92 | $1,448,000.00 |
DisclosureSEC source: 0001127602-24-026735 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $83.83 | $167,660.00 |
DisclosureSEC source: 0001127602-24-024958 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,189 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 23:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $57.92 | $0.00 |
DisclosureSEC source: 0001127602-24-023946 · form4.xml · derivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,670 Underlying: Common Stock · 25,000 shares Expires 2032-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023. F2 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 23:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 21,246 | $84.50 | $1,795,287.00 |
DisclosureSEC source: 0001127602-24-023946 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,189 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 23:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 25,000 | $57.92 | $1,448,000.00 |
DisclosureSEC source: 0001127602-24-023946 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:33 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,821 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023821 · form4.xml · derivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,573 Underlying: Common Stock · 3,821 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:33 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,766 | $81.44 | $143,823.04 |
DisclosureSEC source: 0001127602-24-023821 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,435 Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:33 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,821 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023821 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 00:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $68.63 | $137,260.00 |
DisclosureSEC source: 0001127602-24-019650 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,380 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018413 · form4.xml · derivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,394 Underlying: Common Stock · 3,820 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,744 | $65.25 | $113,796.00 |
DisclosureSEC source: 0001127602-24-018413 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,380 Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018413 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:07 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 51,459 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001104659-24-069636 · tm2416701-3_4seq1.xml · derivative · entry 1 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,459 Underlying: Series A Common Stock · 51,459 shares Expires 2034-06-04 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 5, 2024, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 22:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $72.96 | $145,920.00 |
DisclosureSEC source: 0001127602-24-011987 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,304 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 01:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 17,640 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-009546 · form4.xml · derivative · entry 7 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,214 Underlying: Common Stock · 17,640 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 01:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 89,660 | $0.00 Strike: $75.12 | $0.00 |
DisclosureSEC source: 0001127602-24-009546 · form4.xml · derivative · entry 6 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,660 Underlying: Common Stock · 89,660 shares Expires 2034-03-10 F4 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 01:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 6,946 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-009546 · form4.xml · derivative · entry 5 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,574 Underlying: Common Stock · 6,946 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 01:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-009546 · form4.xml · derivative · entry 4 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,520 Underlying: Common Stock · 3,455 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 01:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 4,803 | $75.12 | $360,801.36 |
DisclosureSEC source: 0001127602-24-009546 · form4.xml · nonDerivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,304 Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 01:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 6,946 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-009546 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 01:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-009546 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 29, 2024 Filed Feb 29, 2024 23:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 8,230 | $72.74 | $598,623.86 |
DisclosureSEC source: 0001127602-24-007678 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,706 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023. F2 · price: Sale prices reported for the transactions reported here range from $72.454 to $72.88. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. F3 · balance_after: Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 23:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $73.18 | $146,360.00 |
DisclosureSEC source: 0001127602-24-007678 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,936 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 19:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 23,709 | $78.26 | $1,855,466.34 |
DisclosureSEC source: 0001127602-24-003044 · form4.xml · nonDerivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,616 Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 19:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 56,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003044 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,325 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2021. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 19:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 20,229 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003044 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,701 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2022 and March 10, 2023. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| December 10, 2023 Filed Dec 12, 2023 00:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,779 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-029247 · form4.xml · derivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,975 Underlying: Common Stock · 2,779 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.